In two previous blogs we discussed
alpha adrenergic and
beta adrenergic blockers, medications that inhibit various actions of the sympathetic nervous system. In this blog, we’ll take a look at adrenergic
agonists known as sympathomimetic agents that have the opposite effect. Let’s review how they work.
Basic Review
Adrenergic drugs are substances that can either simulate or impede the actions of the sympathetic nervous system. They accomplish this by influencing the release or activity of the hormones norepinephrine (noradrenaline) and epinephrine (adrenaline) (Brittanica, 2018). These hormones, which are secreted by the adrenal gland, are responsible for the body’s “fight-or-flight” response, causing a constriction of blood vessels, a rise in blood pressure, and an increase in heart rate and force of cardiac contractions. Sympathomimetic agents simulate the action of the sympathetic nervous system and enhance these effects.
Mechanism of Action
In normal sympathetic nervous system physiology, impulses travel down the pre-synaptic neuron where cellular changes occur. Neurotransmitters are released at the synapse and trigger adrenoreceptors located on the post-synaptic nerve. Adrenergic agonists have three mechanisms of action: direct-acting, indirect-acting, or dual-acting.
Direct-acting sympathomimetics imitate normal physiology and directly activate the adrenergic receptors. They are classified based on their activity on specific adrenoreceptors: alpha-1, alpha-2, beta-1, and beta-2.
- Alpha-1 (α1) agonists contract most vascular smooth muscle
- Alpha-2 (α2) agonists contract mixed smooth muscle
- Beta-1 (β1) agonists increase heart rate
- Beta-2 (β2) agonists relax respiratory and uterine smooth muscle
Indirect-acting adrenergic agonists work in three different ways. They can 1. stimulate and increase the release of neurotransmitters such as norepinephrine from the nerve endings into the synapses; 2. decrease the re-uptake of neurotransmitters into the pre-synaptic nerve; and 3. decrease the enzymatic metabolism of neurotransmitters. Indirect-acting sympathomimetics include drugs such as amphetamines and cocaine (Farzam, Kidron & Lakhkar, 2022).
Dual-acting or
mixed-action adrenergics stimulate both adrenergic receptor sites and the release of norepinephrine from nerve endings. Dual-acting medications include ephedrine and pseudoephedrine.
Examples of Direct-Acting Adrenergic Agonists |
Drug Name |
Receptor |
Indication |
Phenylephrine |
α1 |
Decongestant, vasopressor |
Oxymetazoline |
α1, α2 |
Decongestant, rosacea |
Methyldopa |
α2 |
Hypertension, gestational hypertension |
Clonidine |
α2 |
Hypertention, attention deficit hyperactivity disorder (ADHD) |
Dexmedetomidine |
α2 |
Sedation |
Dobutamine |
β1 |
Cardiogenic shock and heart failure |
Bronchodilators (i.e. Albuterol) |
β2 |
Obstructive lung disease, asthma |
Mirabegron |
β3 receptors in the bladder |
Overactive bladder (urinary incontinence and frequency) |
Norepinephrine |
Non-selective
(α1, α2, β1) |
Shock, hypotension |
Epinephrine |
Non-selective
(α1, α2, β1, β2) |
Cardiac arrest, anaphylaxis, croup |
Dopamine |
Non-selective (α1, β1) |
Hypotension, bradycardia, cardiac arrest |
Isoproterenol |
Non-selective
(β1, β2) |
Bradycardia, heart block |
Nursing Considerations
When administering adrendergic agonists, be sure to monitor for adverse effects such as hypertension and reflex bradycardia (α
1); hypotension, dry mouth, and sedation (α
2); tachycardia, palpitations, tachyarrhythmias, and anxiety (β
1); tremors and tachycardia (β
2). Patients taking alpha-2 agonists are at risk for substance abuse while those taking beta-2 agonists should be monitored for paradoxical bronchospasm.
For complete information, please consult the drug’s specific package insert or the
Nursing2022 Drug Handbook® + Drug Updates.
More Reading & Resources
Tags :